Is there any interest in a new BRAF–MEK inhibitor combination in melanoma?
Is there any interest in a new BRAF–MEK inhibitor combination in melanoma?
About this item
Full title
Author / Creator
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
A press release from Array BioPharma and Pierre Fabre on Feb 8, 2018,5 announced results showing an overall survival benefit of the combination over vemurafenib alone, which have not yet been presented or published.Since encorafenib was shown in early phase trials to be tolerated at a higher dose in combination than as a monotherapy, 450 mg per day...
Alternative Titles
Full title
Is there any interest in a new BRAF–MEK inhibitor combination in melanoma?
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2018665744
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2018665744
Other Identifiers
ISSN
1470-2045
E-ISSN
1474-5488
DOI
10.1016/S1470-2045(18)30161-X
